EVALUATION OF 2'-DCF IN RECOMBINANT LEUKOCYTE IFN ALPHA IN HAIRY CELL LEUKEMIA

毛细胞性白血病最近被发现对重组人 阿尔法干扰素。这种药物能够在体内诱导完全反应 患有这种疾病的患者，但早期结果表明，这种药物是 不能治愈疾病或使所有病人都有反应 一直都在。因此，我们目前正在调查使用 重组α干扰素联合2‘-脱氧辅酶A霉素，另一种 新近发现的药物对毛细胞白血病有显著的活性。 这种组合方法似乎特别有吸引力，因为它很小 对α干扰素耐药的患者数量对 脱氧考福霉素。虽然在这种疾病中非常活跃，但脱氧考福霉素 还有很大的毒性。我们正在低位注射脱氧考福霉素 每周一次，连续三周，然后每天一个月 重组α干扰素。通过这种机制，我们希望避免 使用脱氧考福霉素的累积毒性，但仍能服用 具有抗白血病作用快的优点。通过中断DCF治疗， 我们希望限制与这种药物相关的毒性。然而，虽然 患者正在从DCF相关毒性中恢复，继续抗白血病 以α干扰素形式进行的治疗将继续进行。通过这种方式，我们 希望利用脱氧辅酶A的有益方面和 干扰素，同时最小化每种干扰素的负面影响 毒品。 到目前为止，已有8名患者进入这项研究，正如预期的那样，所有患者 患者表现出早期的反应迹象。严重的骨髓抑制 由于脱氧考福霉素已在所有患者中观察到。两名患者 最初的8名患者已被允许接受抗菌素治疗 粒细胞减少症和发烧。现在评论程度或程度还为时过早 响应的持续时间。

Hairy cell leukemia has recently been found to be responsive to recombinant alpha interferon. This drug is capable of inducing complete responses in patients with this disease, but the early results suggest that this drug is incapable of curing the disease or of making all patients respond continuously. As a result, we are currently investigating the use of combining recombinant alpha interferon with 2'-deoxycoformycin, another drug recently found to have significant activity in hairy cell leukemia. This combination approach appears to be particularly attractive since small numbers of patients resistant to alpha interferon have responded to deoxycoformycin. Although very active in this disease, deoxycoformycin has significant toxicity as well. We are administering deoxycoformycin in low doses weekly for three consecutive weeks followed by one month of daily recombinant alpha interferon. By this mechanism we hope to avoid the cumulative toxicity with deoxycoformycin and yet still be able to take advantage of its rapid antileukemic effect. By interrupting dCF therapy, we hope to limit the toxicity related to this drug. However, while patients are recovering from dCF-related toxicity, continuing antileukemic therapy in the form of alpha interferon will be continued. In this way, we hope to take advantage of the beneficial aspects of deoxycoformycin and interferon while at the same time minimumizing the negative aspects of each drug. So far eight patients have been admitted to this study, and as expected all patients are showing early signs of response. Significant myelosuppression due to deoxycoformycin has been observed in all patients. Two patients of the initial eight have been admitted to receive antibotics for granulocytopenia and fever. It is too early to comment on the extent or duration of response.